In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright.
The English High Court judgment in Lilly v Janssen,  EWHC 1737(Pat) is a timely reminder of the difficulties of defending broad claims in the pharmaceutical and life science area.
Failure to enable the invention to be performed without undue burden is often referred to as “classical insufficiency” and failure to enable the invention to be performed over the whole scope of the claim is often referred to as “excessive claim breadth” (or Biogen) insufficiency.
Janssen was the proprietor of a patent claiming the use of antibodies to the peptide Aß for the treatment of diseases characterised by amyloid deposit, such as Alzheimer’s disease. Lilly sought a declaration that use of the Aß antibody, solanezumab, which Lilly currently has in Phase 3 development for the treatment of Alzheimer’s disease, would not infringe Janssen’s patent.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
patent claims, EPO, Pfizer, Novartis, Supreme Court, Federal Circuit